Characteristics of Primary Tumor, Metastatic Lesions, and Treatment
| Characteristic | Number of patients | Percentage of patients |
| Primary site of tumor | ||
| Small bowel | 19 | 63.3 |
| Pancreas | 3 | 10.0 |
| Lung | 2 | 6.7 |
| Appendix | 1 | 3.3 |
| Colon | 1 | 3.3 |
| Unknown | 4 | 13.3 |
| Primary tumor present | ||
| First scan | 16 | 53.3 |
| Second scan | 10 | 33.3 |
| Tumor grading | ||
| Grade I | 4 | 13.3 |
| Grade II | 12 | 40.0 |
| Grade III | 2 | 6.7 |
| N/A | 12 | 40.0 |
| Percentage of Ki-67 | ||
| <5 | 3 | 10.0 |
| 5–10 | 6 | 20.0 |
| 10–20 | 2 | 6.7 |
| 20–30 | 3 | 10.0 |
| N/A | 16 | 53.3 |
| Treatment | ||
| No treatment | 19 | 63.3 |
| Tumor resection | 10 | 33.3 |
| Surgery + SIR-Spheres | 1 | 3.3 |
| Interval treatment (other than Sandostatin LAR) | ||
| No treatment | 21 | 70.0 |
| Surgery | 6 | 20.0 |
| Chemotherapy | 3 | 10.0 |
| 68Ga-DOTATATE PET/CT result | ||
| <3 focal lesions | ||
| First scan | 5 | 16.7 |
| Second scan | 6 | 20.0 |
| ≥3 focal lesions | ||
| First scan | 25 | 83.3 |
| Second scan | 24 | 80.0 |
| Metastatic involvement* | ||
| Liver | ||
| First scan | 20 | 66.7 |
| Second scan | 21 | 70.0 |
| Lymph node | ||
| First scan | 21 | 70.0 |
| Second scan | 23 | 76.7 |
| Lung | ||
| First scan | 2 | 6.7 |
| Second scan | 2 | 6.7 |
| Bone | ||
| First scan | 6 | 20.0 |
| Second scan | 7 | 23.3 |
| Adnexa | ||
| First scan | 1 | 3.3 |
| Second scan | 1 | 3.3 |
| Pancreas | ||
| First scan | 1 | 3.3 |
| Second scan | 1 | 3.3 |
| Analyzed lesions† | ||
| Total | 160 | |
| Liver | 73 | |
| Lymph node | 60 | |
| Bone | 23 | |
| Lung | 2 | |
| Other | 2 |